Health Technology · Pharmaceuticals: Major · NSE: ASTRAZEN · data 2026-10-09
AstraZeneca Pharma India Limited
Health check: Average (4.3/10 on quality, valuation vs sector, growth and momentum).
Open full analysis — chart, results, balance sheet, red flags →Key figures
Price
₹5,837
Market cap
₹14,260 cr
P/E
86
P/B
—
ROE
23.9%
ROCE
25.5%
Debt / equity
0.13
Dividend yield
0.63%
1-year return
-37.0%
52-week high
₹9,849.5
52-week low
₹5,640
Operating margin
9.9%
Growth
| Revenue (last 12 months) | ₹2,432 cr |
| Net profit (last 12 months) | ₹170 cr |
| Sales growth, 3 years (yearly) | 31.4% |
| Profit growth, 3 years (yearly) | 23.6% |
Similar companies
Alembic Pharmaceuticals Limited (APLLTD) · NATCO Pharma Limited (NATCOPHARM) · Jubilant Pharmova Limited (JUBLPHARMA) · Indegene Limited (INDGN) · Marksans Pharma Limited (MARKSANS)
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open ASTRAZEN in NSE Scanner →